Bath & Body Works (NYSE:BBWI) Price Target Raised to $24.00 at JPMorgan Chase & Co.

Bath & Body Works (NYSE:BBWI) had its price objective upped by JPMorgan Chase & Co. from $22.00 to $24.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 19.43% from the stock’s current price.

Several other equities analysts have also commented on BBWI. TD Cowen raised their price objective on Bath & Body Works from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Raymond James Financial reiterated a “market perform” rating on shares of Bath & Body Works in a research note on Wednesday, May 27th. Jefferies Financial Group lifted their price target on shares of Bath & Body Works from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. Citigroup raised shares of Bath & Body Works from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Tuesday. Finally, Weiss Ratings upgraded shares of Bath & Body Works from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bath & Body Works presently has a consensus rating of “Hold” and a consensus price target of $22.57.

Bath & Body Works Stock Up 6.8%

Shares of BBWI traded up $1.28 during trading hours on Tuesday, reaching $20.09. 1,626,757 shares of the company traded hands, compared to its average volume of 5,609,302. Bath & Body Works has a 12 month low of $14.27 and a 12 month high of $32.32. The company’s fifty day moving average price is $20.38 and its two-hundred day moving average price is $20.14. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 5.63, a price-to-earnings-growth ratio of 1.92 and a beta of 1.38.

Bath & Body Works (NYSE:BBWI) last released its quarterly earnings results on Wednesday, May 27th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.03. The company had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.36 billion. Bath & Body Works had a net margin of 10.03% and a negative return on equity of 45.34%. Bath & Body Works’s revenue was down 3.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 earnings per share. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. On average, analysts expect that Bath & Body Works will post 2.63 EPS for the current year.

Hedge Funds Weigh In On Bath & Body Works

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada increased its stake in Bath & Body Works by 92.8% during the 1st quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock valued at $1,815,000 after purchasing an additional 28,815 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Bath & Body Works by 15.7% during the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock valued at $19,586,000 after buying an additional 87,529 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Bath & Body Works by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock valued at $17,063,000 after acquiring an additional 36,684 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Bath & Body Works during the first quarter valued at approximately $1,155,000. Finally, Geneos Wealth Management Inc. raised its holdings in Bath & Body Works by 217.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after acquiring an additional 801 shares during the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.